loadpatents
name:-0.03419303894043
name:-0.0099959373474121
name:-0.00041985511779785
Masferrer; Jaime L. Patent Filings

Masferrer; Jaime L.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Masferrer; Jaime L..The latest application filed is for "use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash)".

Company Profile
0.9.23
  • Masferrer; Jaime L. - Cambridge MA
  • Masferrer; Jaime L. - Chesterfield MO
  • Masferrer; Jaime L. - Ballwin MO
  • Masferrer, Jaime L. - St. Louis MO
  • Masferrer; Jaime L - Ballwin MO
  • Masferrer; Jaime L. - Tarrytown NY
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
Grant 11,357,777 - Im , et al. June 14, 2
2022-06-14
USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH)
App 20210161893 - Im; G-Yoon Jamie ;   et al.
2021-06-03
Pyrazole analogs
Grant 7,772,269 - Graneto , et al. August 10, 2
2010-08-10
Pyrazole Analogs
App 20080125474 - Graneto; Mathew J. ;   et al.
2008-05-29
Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
App 20060252766 - Masferrer; Jaime L. ;   et al.
2006-11-09
Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
App 20050227929 - Masferrer, Jaime L.
2005-10-13
Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
App 20050187172 - Masferrer, Jaime L.
2005-08-25
Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
Grant 6,916,800 - McKearn , et al. July 12, 2
2005-07-12
Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia
App 20050085477 - Masferrer, Jaime L.
2005-04-21
Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent
App 20050058725 - McKearn, John P. ;   et al.
2005-03-17
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
Grant 6,858,598 - McKearn , et al. February 22, 2
2005-02-22
Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
App 20050037090 - McKearn, John P. ;   et al.
2005-02-17
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
Grant 6,833,373 - McKearn , et al. December 21, 2
2004-12-21
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
App 20040234624 - McKearn, John P. ;   et al.
2004-11-25
Carbonic anhydrase inhibitor
App 20040198781 - Masferrer, Jaime L. ;   et al.
2004-10-07
Antiangiogenic combination therapy for the treatment of cancer
App 20040127539 - Masferrer, Jaime L.
2004-07-01
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
App 20040122011 - Masferrer, Jaime L. ;   et al.
2004-06-24
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
App 20040072889 - Masferrer, Jaime L.
2004-04-15
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
App 20040067992 - Masferrer, Jaime L. ;   et al.
2004-04-08
Combination therapy of radiation and a COX-2 inhibitor for the treatment of neoplasia
App 20040053935 - Masferrer, Jaime L.
2004-03-18
Combination therapy of radiation and a COX-2 inhibitor for the treatment of neoplasia
App 20040053934 - Masferrer, Jaime L.
2004-03-18
Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
App 20040053900 - Masferrer, Jaime L.
2004-03-18
Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
Grant 6,689,787 - McKearn , et al. February 10, 2
2004-02-10
Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
App 20030225150 - Masferrer, Jaime L.
2003-12-04
Methods for treating carbonic anhydrase mediated disorders
App 20030220376 - Masferrer, Jaime L. ;   et al.
2003-11-27
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
Grant 6,649,645 - McKearn , et al. November 18, 2
2003-11-18
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
App 20030119895 - Masferrer, Jaime L. ;   et al.
2003-06-26
Carbonic anhydrase inhibitor
App 20030100594 - Masferrer, Jaime L. ;   et al.
2003-05-29
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
App 20030013739 - Masferrer, Jaime L.
2003-01-16
Antiangiogenic combination therapy for the treatment of cancer
App 20020103141 - McKearn, John P. ;   et al.
2002-08-01
2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
Grant 5,380,738 - Norman , et al. January 10, 1
1995-01-10
Novel, long-duration treatment for glaucoma
Grant 4,906,467 - Schwartzman , et al. March 6, 1
1990-03-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed